论文信息 - BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. - 字舞流文

BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.

S. Oudard | Y. Vano | R. Elaidi | C. Thibault | E. Braychenko | A. Simonaggio | N. Epaillard | M. Moreira | Fouzia Azzouz | Cheng-Ming Sun